Retatrutide and trizepatide represent a new class of medications that target both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These dual receptor agonists https://woodylgmb643517.wikiexpression.com/user